EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Mechanism of Apigenin against breast cancer stem cells: network pharmacology and experimental validation

Mengdie Ou, Zhicheng Deng, Yonghui Shi, Jianxiong He, Zicong Ye, Ming Guo, Guohua Cheng, Junyan Wu, Li Lv

Frontiers in Pharmacology · 13.11.2024 · 15

DOI: 10.3389/fphar.2024.1496664 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 13.11.2024. Verfasst von Mengdie Ou und 8 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Jinan University, Guangzhou, China. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Apigenin (API), a traditionally sourced flavonoid, is recognized for its anti-neoplastic properties. Despite well-documented effects on tumorigenesis, the detailed therapeutic impact on breast cancer stem cells (BCSCs) and the associated molecular mechanisms are yet to be clarified. The objective of this study is to elucidate the therapeutic effects of API on BCSCs and to uncover its molecular mechanisms through network pharmacology and experimental validation. Interactions of API with candidate targets were examined through target screening, enrichment analysis, construction of protein-protein interaction networks, and molecular docking. MCF-7-derived BCSCs were utilized as a model system to investigate and substantiate the anti-BCSC effects of API and the underlying mechanism. Molecular docking studies have shown that API and TP53 exhibit favorable binding affinity. Compared with the negative control group, API effectively suppressed the expression of BCSC-related proteins such as ALDH1A1, NANOG, EpCAM, and MYC, downregulated p-PI3K and p-AKT, and upregulated p53. This study demonstrates that API can play an anti-BCSC role by regulating the PI3K/AKT/p53 pathway in BCSCs of MCF-7 cells, highlighting its potential as a therapeutic agent for targeting BCSCs.

Schlagwörter

Stichwörter der Autor:innen

ApigeninMCF-7 cellsPI3K/AKTbreast cancer stem cellsmolecular dockingnetwork pharmacologyp53

Autor:innen und Institutionen

  • School of Pharmacy, Jinan University, Guangzhou, China.
  • Department of Pharmacy, Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China.
  • Guangdong Provincial Key Laboratory of Cancer Pathogenesis and Precision Diagnosis and Treatment, Shenshan Medical Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Shanwei, China.

Zitieren

APA

Ou, M., Deng, Z., Shi, Y., He, J., Ye, Z., Guo, M., Cheng, G., Wu, J., & Lv, L. (2024). Mechanism of Apigenin against breast cancer stem cells: network pharmacology and experimental validation. Frontiers in Pharmacology, 15. https://doi.org/10.3389/fphar.2024.1496664

Vancouver

Ou M, Deng Z, Shi Y, He J, Ye Z, Guo M, et al. Mechanism of Apigenin against breast cancer stem cells: network pharmacology and experimental validation. Frontiers in Pharmacology. 2024;15. doi:10.3389/fphar.2024.1496664

BibTeX
@article{Ou2024,
  author = {Ou, Mengdie and Deng, Zhicheng and Shi, Yonghui and He, Jianxiong and Ye, Zicong and Guo, Ming and Cheng, Guohua and Wu, Junyan and Lv, Li},
  title = {Mechanism of Apigenin against breast cancer stem cells: network pharmacology and experimental validation},
  journal = {Frontiers in Pharmacology},
  year = {2024},
  volume = {15},
  doi = {10.3389/fphar.2024.1496664}
}
Kostenlos starten →